Oramed Pharmaceuticals Inc (NASDAQ:ORMP) on Focus After Report of More Shorts

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Logo

Investors sentiment decreased to 1 in Q2 2019. Its down 0.40, from 1.4 in 2019Q1. It turned negative, as 2 investors sold Oramed Pharmaceuticals Inc. shares while 5 reduced holdings. 3 funds opened positions while 4 raised stakes. 808,053 shares or 22.59% less from 1.04 million shares in 2019Q1 were reported.
Pnc Fincl Ser Grp Inc Inc stated it has 0% of its portfolio in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Barclays Pcl holds 41,186 shares or 0% of its portfolio. Sabby Mgmt Llc holds 1.6% of its portfolio in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) for 354,713 shares. Bancorp Of America Corporation De holds 0% of its portfolio in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) for 1,236 shares. Jfs Wealth Advisors Ltd Liability Corporation invested in 500 shares. Panagora Asset Mngmt Inc invested in 12,864 shares. Glenmede Commerce Na owns 20,000 shares. Tower Rech Limited Co (Trc) reported 0% stake. Renaissance Technologies Ltd Liability reported 158,098 shares or 0% of all its holdings. Fincl Bank Of Montreal Can invested 0% of its portfolio in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Morgan Stanley, a New York-based fund reported 28,252 shares. Blackrock holds 0% or 74,291 shares in its portfolio. Wells Fargo & Mn owns 4,950 shares. Jane Street Group Ltd Liability Corp holds 0% or 43,212 shares. Dafna Capital Mngmt Limited Com has 16,000 shares for 0.02% of their portfolio.

Since July 11, 2019, it had 3 insider purchases, and 0 insider sales for $272,961 activity.

The stock of Oramed Pharmaceuticals Inc (NASDAQ:ORMP) registered an increase of 18.31% in short interest. ORMP’s total short interest was 49,100 shares in October as published by FINRA. Its up 18.31% from 41,500 shares, reported previously. With 50,100 shares average volume, it will take short sellers 1 days to cover their ORMP’s short positions. The short interest to Oramed Pharmaceuticals Inc’s float is 0.4%.

The stock increased 1.60% or $0.05 during the last trading session, reaching $3.18. About 19,250 shares traded. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has declined 34.17% since October 9, 2018 and is downtrending. It has underperformed by 34.17% the S&P500.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company has market cap of $55.28 million. The Company’s product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. It currently has negative earnings. The firm operates primarily in Israel.

More notable recent Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) news were published by: Finance.Yahoo.com which released: “Have Insiders Been Selling Vocera Communications, Inc. (NYSE:VCRA) Shares This Year? – Yahoo Finance” on June 10, 2019, also Finance.Yahoo.com with their article: “Seattle Genetics Inc (SGEN) President and CEO Clay B Siegall Sold $1.3 million of Shares – Yahoo Finance” published on July 10, 2019, Finance.Yahoo.com published: “Energy distributor UGI’s unit to acquire Columbia Midstream for $1.28 bln – Yahoo Finance” on July 02, 2019. More interesting news about Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) were released by: Finance.Yahoo.com and their article: “Vanda Pharmaceuticals Returns to Profitability in Q2 – Yahoo Finance” published on August 05, 2019 as well as Finance.Yahoo.com‘s news article titled: “We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Needs To Drive Business Growth Carefully – Yahoo Finance” with publication date: September 20, 2019.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.